Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.2.1.13 (
glyceraldehyde-3-phosphate dehydrogenase
)
6,511
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Growth factors and growth factor receptors are involved in tumor progression. The fibroblast growth factor receptor 2 gene encodes distinct isoforms. The isoforms which bind
KGF
(keratinocyte growth factor or
FGF-7
) are called
KGF
-R or FGFR2b.
KGF
-R is expressed in different epithelia and is involved in the control of epithelial-mesenchymal interactions. Expression of
KGF
-R mRNA was examined in normal human bladder and transitional cell carcinoma of the bladder (TCC) by semi-quantitative RT-PCR using TFIID and
GAPDH
as internal standards. In normal bladder, the
KGF
-R mRNA was detected in the urothelium but not in the underlying stroma. In TCCs, the level of
KGF
-R mRNA was generally either normal or low. Eighteen out of 54 TCCs had a
KGF
-R mRNA level below 30% of that found in normal urothelium. This decrease in
KGF
-R mRNA was not accompanied by an increase in BEK (FGFR2c) mRNA, the other major splice variant of the fibroblast growth factor receptor 2 gene. Expression of the
KGF
-R was also monitored by immunohistochemistry using a functional
KGF
-immunoglobulin chimera. The receptor was uniformly expressed throughout the normal urothelium except for the umbrella cells. Immunoreactivity for
KGF
-R was found to be negative in tumors with low levels of
KGF
-R mRNA, while the peritumoral normal urothelium was positive. Among patients with muscle invasive tumors, those exhibiting a low level of
KGF
-R mRNA had a significantly higher proportion of cancer deaths. Our results suggest that decreased expression of
KGF
-R can be considered as a marker of tumor progression in muscle invasive TCCs.
...
PMID:Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. 901 18